1. PFE:NYQ

    Pfizer Inc

    USD

    33.57

    Today's change

    0.17 / +0.51%

    1 year change

    -1.61%

    As of May 05 2016 21:00 BST. Data delayed by at least 15 minutes.

Search for Pfizer Inc and
  1. May 3, 2016

    Pfizer weighs split to cut tax bill

    Pfizer is looking for new ways to cut its US tax bill including moving part of its business overseas following a...

  2. Fast FT

    May 3, 2016

    Pfizer hunts for new ways to cut tax bill

    Ian Read, chief executive of Pfizer, has suggested moving part of the drugmaker to a low-tax jurisdiction following a...

Special Reports

  1. FT Health: Vaccines

    In today’s connected world, where outbreaks of infectious disease can spread faster th...
  2. Corporate Longevity

    The FT launches a global investigation into the mixture of innovation and focus that c...
Search more Special Reports on this topic.

  1. Fast FT

    May 3, 2016

    Pfizer tops forecasts, lifts guidance

    Shares in Pfizer have jumped almost 3 per cent in pre-market trading after the US drugmaker reported first quarter...

  2. Fast FT

    May 3, 2016

    Markets: FX machinations lead to cautious mood

    Forex is in focus as the yen hits a fresh 18-month high, the dollar index slips to a 15-month low and the Aussie is...

  3. April 28, 2016

    What pawnbrokers can teach central banks

    Three decades ago, the club of triple A-rated American corporate borrowers was a busy place. About 60 big companies,...

  4. April 27, 2016

    Daniel Loeb warns of hedge fund ‘killing field’

    One of the most powerful US hedge fund managers believes that the industry is in “first innings of a washout” after a...

  5. April 25, 2016

    Drug prices: Tweaking the formula

    What is the value of a human life? It is one of the most fraught questions in public policy as governments around the...

  6. April 25, 2016

    Vaccine development needs global alliance

    Who has saved the most lives in human history? Claims can be made for various scientific pioneers and political...

  7. April 25, 2016

    Vaccines are among big pharma’s best-selling products

    Ask people to name Pfizer’s best-selling product and many would opt for one of its most famous drugs: Viagra, for...

  8. Fast FT

    April 19, 2016

    US M&A off to worst Q2 since 2009

    Not much for banks to cheer about. Following a string of lacklustre results from big banks, hopes for investment...

  9. April 11, 2016

    M&A crackdown puts bond investors on edge

    A crackdown on mergers and acquisitions has investors on edge over the potential that competition for corporate bonds...

  10. April 7, 2016

    US takes tougher stance on deals under Obama

    The Obama administration’s bid to scuttle the $25bn takeover of Baker Hughes by Halliburton is less a sudden turn...

  11. April 7, 2016

    M&A deals worth $370bn torpedoed by Obama administration

    US companies have abandoned $370bn of large deals since President Barack Obama came into power in 2009, after...

  12. April 7, 2016

    A real-world solution to the tax repatriation ruckus

    There are not many questions on which a man such as Tim Cook, chief executive officer of Apple , would agree with...

  13. April 6, 2016

    Collapse of $160bn Pfizer and Allergan merger shocks corporate US

    The collapse of Pfizer’s $160bn merger with Allergan on Wednesday brought the total value of abandoned deals this year...

  14. April 6, 2016

    Pfizer chief’s long quest for tax inversion ends in failure

    For more than two years, Ian Read, the plain-speaking Scottish chief executive of Pfizer, had been on a mission to find...

  15. April 6, 2016

    M&A failures: deep breaths

    What were they thinking? The largest US cable TV company tried to buy the second largest. The second and third-largest...

  16. Fast FT

    April 6, 2016

    2016 M&A withdrawals highest since '07

    The White House’s efforts to deter tax inversion deals saw Pfizer abandon its $160bn pursuit of botox maker Allergan on...

  17. April 6, 2016

    US Treasury shatters Pfizer chief Ian Read’s merger dreams

    Ian Read cannot be faulted for his persistence. For more than two years the chief executive of Pfizer has been...

  18. April 6, 2016

    Pfizer merger collapse is serious failure of management

    Anyone who cares about decent management, long-term corporate commitment and the reputation of business will take grim...

  19. April 6, 2016

    Pfizer: plan C

    The problem is growth, and has been ever since Lipitor, the biggest-selling drug in history, lost patent protection...

  20. Fast FT

    April 6, 2016

    Pfizer, Allergan formally end $160bn merger

    It’s officially over. The Viagra-meets-Botox merger is not meant to be. Pfizer and Allergan confirmed on Wednesday that...

  21. Fast FT

    April 6, 2016

    Pfizer to kill $160bn Allergan merger

    Pfizer has decided to kill its $160bn merger with Allergan, after the Obama administration took new steps to bring an...

  22. April 5, 2016

    US crackdown on inversions came ‘out of left field’

    For the past couple of years, President Barack Obama has been accused of failing to prevent US companies from...

  23. April 5, 2016

    Hedge funds knocked by Allergan’s fall

    Four of the US’s largest hedge funds saw as much as $900m knocked off the value of their holdings in Allergan when new...

  24. April 5, 2016

    Washington slams shut Pfizer’s tax loophole

    When a public outcry greeted the announcement of Pfizer’s tax-driven $160bn takeover of Allergan last year, Ian Read,...

  25. April 5, 2016

    Treasury’s shot at tax inversions will cause collateral damage

    The US Treasury has taken aim at inversions, imposing new curbs on deals in which American companies look to cut their...

  26. April 5, 2016

    Allergan shares drop on tax inversion curbs

    Allergan shares tumbled 18 per cent on Tuesday morning as investors concluded that the Obama administration’s plans to...

  27. April 5, 2016

    Tax inversions: bloody nightmare

    Vampires are not the most popular creatures, working as they do under the cover of darkness to drain the lifeblood of...

  28. April 5, 2016

    Tax inversions: what the new rules mean

    What’s been announced? On Monday, the US Treasury said it was taking additional steps to “rein in inversions” —...

  29. FT Alphaville

    April 5, 2016

    Markets Live: Tuesday, 5th April, 2016

    This Markets Live session ended at 12:04 on 5 Apr 2016. Participants in this session were: Paul Murphy and Bryce Elder...

  30. Fast FT

    April 4, 2016

    Allergan tumbles 20% amid US tax inversion move

    Allergan shares tumbled by 20 per cent late on Monday after the US government took action to limit the benefits of...

  31. Fast FT

    March 29, 2016

    British drugmakers receive drug approvals in Japan

    UK pharmaceuticals giants AstraZeneca and GlaxoSmithKline have both received some good news from Japanese regulators...

  32. Fast FT

    March 29, 2016

    FirstFT - The criminals paid not to kill

    Here’s a taste of today’s FirstFT email. You can sign up to receive it here. Strains of a scandal For years, the US...

  33. March 28, 2016

    Valeant: The harder they fall

    In the spring of 2014, as the drugs industry was gripped by a dealmaking frenzy, executives from Pfizer sat down for...

  34. March 17, 2016

    GSK: wheel of fortune

    He played a bad hand well is an honourable epitaph for a private life. It will not do for the tenure of a public...

  35. March 7, 2016

    China’s biotech revolution ushered in by entrepreneurs

    When Samantha Du returned to her native China in 2001 with a mission to build a pharmaceuticals company, the move...

  36. February 16, 2016

    Pharma whistleblower takes total payouts close to $100m

    A Louisiana doctor who has brought a series of whistleblower lawsuits against pharmaceuticals companies is in line for...

  37. Fast FT

    February 10, 2016

    Mylan to buy Meda in $9.9bn deal

    Mylan, the generic drugmaker, on Wednesday unveiled plans to buy Sweden’s Meda for $9.9bn, including debt. The company,...

  38. February 9, 2016

    Pfizer seeks to soothe fears over R&D

    Pfizer’s most senior scientist has moved to quell concerns that the company’s $160bn takeover of Allergan will lead to...

Search for Pfizer Inc and